

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MERCK SHARP & DOHME LLC,
Petitioner

v.

HALOZYME INC.,
Patent Owner

Case PGR2025-00050
U.S. Patent No. 12,077,791

PATENT OWNER RESPONSE
UNDER 37 C.F.R. § 42.120

Mail Stop “PATENT BOARD”
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

TABLE OF CONTENTS

I.	INTRODUCTION	1
II.	BACKGROUND	7
A.	Patentee’s Experts	7
B.	Technical Background.....	8
C.	The ’791 Patent	12
1.	Key Sequences Referred to in the Patent.....	15
2.	Example 2	16
3.	Examples 3 & 4.....	17
a.	Data on Active Mutants.....	17
b.	The I309 Mutation	19
c.	Data on Inactive Mutants.....	20
d.	Tolerability at Each Position Based on Enzymatic Activity Testing	21
4.	The Patent’s Detailed Structure-Function Mapping Significantly Expands The POSA’s Knowledge Regarding PH20 Residues Critical for Enzymatic Function.....	23
5.	C-Terminal Truncations.....	25
6.	Challenged Claims	26
III.	PERSON OF ORDINARY SKILL IN THE ART	28
IV.	Claim Construction Issues	28
V.	THE SPECIFICATION PROVIDES WRITTEN DESCRIPTION OF THE INVENTION (GROUND 1)	33
A.	The Specification Describes Common Structural Features of the Ten I309 Modified PH20 Variants and Their Subvariants	34
B.	The Specification Provides Structure-Function Correlations Allowing for Single and Multiple Mutations	38
C.	The Example I309 Variants Are Representative of the Claimed 95% Identical Subvariants	42
D.	The Patent Teaches the Effect of C-terminal Truncations.....	46

E.	The Specification Describes Multiply Modified PH20 Polypeptides.	48
F.	<i>AbbVie</i> Is Distinguishable	50
G.	The Petition Fails To Demonstrate That The Challenged Dependent Claims Lack Written Description.....	50
VI.	THE CHALLENGED CLAIMS ARE ENABLED (GROUND 2).....	51
A.	The <i>Wands</i> Factors Weigh in Favor of Enablement	54
1.	Scope of Claims and Nature of the Invention.....	54
2.	Level of Skill in the Art And State of the Art.....	55
3.	Guidance in the Specification and the Presence of Working Examples	57
4.	Predictability of the Field and Quantity of Experimentation ..	58
B.	Specification Enables Credible Use of the Claimed PH20 Variants ..	61
C.	A POSA Could Readily Distinguish Between Active And Inactive Mutants	62
D.	The Challenged Dependent Claims Are Enabled	63
VII.	CONCLUSION.....	64

PATENT OWNER'S UPDATED EXHIBIT LIST

Exhibit No.	Description
2001	Declaration of Barbara Triggs-Raine, Ph.D. in support of Patent Owner Discretionary Denial Brief (WITHDRAWN)
2002	<i>Curriculum Vitae</i> of Barbara Triggs-Raine, Ph.D.
2003	Disclaimer in a Patent under 37 C.F.R. § 1.321(a), filed in U.S. Patent Application No. 18/659,215, July 24, 2025
2004	Sequence listing of U.S. Patent Application No. 18/659,215
2005	"2023 Pharma 50: The 50 largest pharma companies in the world," drugdiscoverytrends.com, accessible at https://www.drugdiscoverytrends.com/2023-pharma-50-largest-companies/ (last accessed April 28, 2025)
2006	"Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results," Merck Press Release, February 4, 2025
2007	"Merck & Company, Inc. Common Stock (new) (MRK)," Nasdaq.com, accessible at https://www.nasdaq.com/market-activity/stocks/mrk (last accessed April 28, 2025)
2008	"Halozyme Therapeutics, Inc. Common Stock (HALO)," Nasdaq.com, accessible at https://www.nasdaq.com/market-activity/stocks/halo (last accessed April 28, 2025)
2009	"Halozyme reports full year 2024 record revenue of \$1.015 billion and Exceeds its Financial Guidance for Royalty Revenue, Adjusted EBITDA and Non-GAAP Diluted EPS," Halozyme.com, accessible at https://ir.halozyme.com/news/news-details/2025/HALOZYME-REPORTS-FULL-YEAR-2024-RECORD-REVENUE-OF-1.015-BILLION-AND-EXCEEDS-ITS-FINANCIAL-GUIDANCE-FOR-ROYALTY-REVENUE-ADJUSTED-EBITDA-AND-NON-GAAP-DILUTED-EPS/default.aspx (last accessed April 28, 2025)

Exhibit No.	Description
2010	“Commercial Products,” Halozyme.com, accessible at https://halozyme.com/commercial-products/ (last accessed April 28, 2025)
2011	“About Us,” Halozyme.com, accessible at https://halozyme.com/about-us/#our-focus (last accessed April 28, 2025)
2012	Complaint for Patent Infringement and Declaratory Judgment of Patent Infringement, <i>Halozyme, Inc. v. Merck Sharp & Dohme Corp.</i> , Civil Action No. 2:25-cv-03179-ES (D.N.J.), filed April 24, 2025
2013	“Alteogen announces amendment to license agreement with MSD,” Alteogen Press Release, February 22, 2025, accessible at https://www.alteogen.com/en/ir_1/?uid=2223&mod=document&pageid=1 (last accessed April 28, 2025)
2014	"Big Pharma's Business Model: Corporate Greed," United States Senate Health, Education, Labor, and Pensions Committee February 6, 2024
2015	"Medicare now negotiating price of drug that costs \$7,100 in US vs. \$900 in Canada," CNN February 6, 2024
2016	Fact Sheet: President Donald J. Trump Announces Actions to Put American Patients First by Lowering Drug Prices and Stopping Foreign Free-riding on American Pharmaceutical Innovation," The White House May 12, 2025 Last accessed August 12, 2025
2017	"Big Pharma Earnings Watch: Merck and Pfizer" February 7, 2025 The Campaign for Sustainable Rx Pricing
2018	Declaration of Tyler C. Liu (<i>served not filed</i>)
2019-2067	<i>Intentionally Left Blank</i>

Exhibit No.	Description
2068	Declaration of Melanie A. Simpson, Ph.D. in Support of Patent Owner's Response
2069	<i>Curriculum Vitae</i> of Melanie A. Simpson, Ph.D.
2070	Declaration of Gregory A. Petsko, Ph.D. in Support of Patent Owner's Response
2071	<i>Curriculum Vitae</i> of Gregory A. Petsko, Ph.D.
2072-2075	<i>Intentionally Left Blank</i>
2076	Transcript of the Deposition of Michael Hecht, Ph.D., August 26, 2025
2077	Transcript of the Deposition of Dr. Sheldon Park, August 7, 2025
2078	Transcript of the Deposition of Dr. Sheldon Park, August 21, 2025
2079	Koehl, P. et al., "Structure-based conformational preferences of amino acids," <i>PNAS</i> , 96(22):12524-12529 (October 26, 1999)
2080	Pommié, C. et al., "IMGT standardized criteria for statistical analysis of immunoglobulin V-REGION amino acid properties," <i>Journal of Molecular Recognition</i> , 17:17-32 (2004)
2081	<i>Intentionally Left Blank</i>
2082	Kyte, J. et al., "A Simple Method for Displaying the Hydropathic Character of a Protein," <i>Journal of Molecular Biology</i> , 157:105-132 (1982)
2083	<i>Assay Guidance Manual</i> , Eli Lilly & Company and the National Center for Advancing Translational Sciences
2084	"The Central Role of Enzymes as Biological Catalysts," NCBI Bookshelf, National Institutes of Health (accessible at https://www.ncbi.nlm.nih.gov/books/NBK9921/ , last accessed September 22, 2025)

Exhibit No.	Description
2085	French, S. et al., “What is a Conservative Substitution?”, <i>Journal of Molecular Evolution</i> , 19:171-175 (1983)
2086	El-Safory, N. et al., “Hyaluronidases, a group of glycosidases: Current and future perspectives,” <i>Carbohydrate Polymers</i> , 81:165-181 (2010)
2087	Lu, J. et al., “Hyaluronidase: structure, mechanism of action, diseases and therapeutic targets,” <i>Molecular Biomedicine</i> , 6:50-77 (2025)
2088	Stern, R. et al., “Mammalian Hyaluronidases,” Hyaluronan Index (2000)
2089	Gmachl, M. et al., “The human sperm protein PH-20 has hyaluronidase activity,” <i>FEBS Letters</i> , 336(3):545-548 (December 1993)
2090	Gmachl, M. et al., “Bee venom hyaluronidase is homologous to a membrane protein of mammalian sperm,” <i>PNAS USA</i> , 90:3569-3573 (April 1993)
2091	Davies, G. et al., “Structures and mechanisms of glycosyl hydrolases,” <i>Current Biology</i> , 3:853-859 (1995)
2092	Marković-Housley, Z. et al., “Crystal Structure of Hyaluronidase, a Major Allergen of Bee Venom,” <i>Structure</i> , 8:1025-1035 (October 2000)
2093	U.S. Patent No. 8,343,487 B2 to Baker et al., issued January 1, 2013
2094	Thermo Scientific Multidrop® 384 User Manual, Rev. 3.4, Thermo Fisher Scientific (October 2008)
2095	<i>Intentionally Left Blank</i>
2096	Frost, G. et al., “A Microtiter-Based Assay for Hyaluronidase Activity Not Requiring Specialized Reagents,” <i>Analytical Biochemistry</i> , 251:263-269 (1997)

Exhibit No.	Description
2097	U.S. Patent Application Publication No. 2005/0260186 A1 to Bookbinder et al., published November 24, 2005
2098	Delpech, B. et al., “Enzyme-Linked Hyaluronectin: A Unique Reagent for Hyaluronan Assay and Tissue Location and for Hyaluronidase Activity Detection,” <i>Analytical Biochemistry</i> , 229:35-41 (1995)
2099	Takahashi, T. et al., “A fluorimetric Morgan-Elson assay method for hyaluronidase activity,” <i>Analytical Biochemistry</i> , 322:257-263 (2003)
2100-2062	<i>Intentionally Left Blank</i>
2163	National Medal of Science in Medicine Citation for Gregory Petsko, 2022 (accessible at https://nationalmedals.org/laureate/gregory-petsko/?amp=1 , last accessed September 19, 2025)
2164	Petsko, G., et al., <i>Protein Structure and Function</i> , New Science Press (2004)
2165	U.S. Patent Application Publication No. 2010/0143457 A1 to Wei et al., published June 10, 2010
2166	Petsko Patent Analysis Data
2167	<i>Intentionally Left Blank</i>
2168	Profile of Gregory A. Petsko, American Academy of Arts and Sciences (accessible at https://www.amacad.org/person/gregory-petsko , last accessed September 22, 2025)
2169	“BLAST Topics,” National Institutes of Health (accessible at https://blast.ncbi.nlm.nih.gov/doc/blast-topics , last accessed September 22, 2025)
2170	Chain, E. et al., “Identity of Hyaluronidase and Spreading Factor,” <i>British Journal of Experimental Pathology</i> , 21(6):324-338 (1940)

Exhibit No.	Description
2171-2173	<i>Intentionally Left Blank</i>
2174	Errata from Park Deposition (introduced during Park deposition and marked by court reporter as “Park 2068”)
2175	Mutational Analysis Table, 2024-11-7, Native Excel File (introduced during Park deposition and marked by court reporter as “Park 2069”)
2176	Mutational Analysis Table, 2024-11-7, PDF File (introduced during Park deposition and marked by court reporter as “Park 2070”)
2177	E-mail Correspondence dated August 14, 2025
2178	1LOH pdb file
2179	1FCV pdb file
2180	2PE4 pdb file
2181	8SMN pdb file
2182	I309L Swiss Model
2183	I309N Swiss Model
2184	I309E Swiss Model
2185	I309G Swiss Model
2186	I309H Swiss Model
2187	I309M Swiss Model
2188	I309Q Swiss Model
2189	I309R Swiss Model
2190	I309S Swiss Model

Exhibit No.	Description
2191	PH20 Swiss Model
2192	<i>Intentionally Left Blank</i>
2193	N47A_N219A_I309N Swiss Model
2194	N47A_N131A_I309N Swiss Model
2195	N47A_N131A_N219A_I309N Swiss Model
2196	N131A_N219A_I309N Swiss Model
2197	Orangutan_I309N Swiss Model
2198	Chimpanzee_I309N Swiss Model
2199	Gibbon_I309N Swiss Model
2200	I309T Swiss Model
2201-2399	<i>Intentionally Left Blank</i>
2400	Merck & Co., Inc. Form 10-Q, Securities and Exchange Commission, November 5, 2025
2401	E-mail Correspondence between Counsel for Petitioner and Patent Owner, January 6, 2026 (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2402	MERCK_PGR00006 - 30November2023 Merck 031988 Master Agreement - executed 4932-6153-3216 1_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2403	MERCK_PGR00056 - MSA - Term 4 - Dechert LLP_Signed_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2404	MERCK_PGR00467 - Mark Stewart Offer Letter_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)

Exhibit No.	Description
2405	MERCK_PGR00052 - Hecht Engagement Letter (7-19)_Signed (Redacted)_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2406	MERCK_PGR00086 - Park Engagement Letter with signature - sjp (redacted)_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2407	“Executive team,” MSD, accessible at http://www.msd.com/company-overview/leadership/executive-team/ (last accessed January 5, 2026)
2408	“Executive team,” Merck, accessible at http://www.merck.com/company-overview/leadership/executive-team/ (last accessed January 5, 2026)
2409	“Board of directors,” MSD, accessible at http://www.msd.com/company-overview/leadership/board-of-directors/ (last accessed January 5, 2026)
2410	“Board of directors,” Merck, accessible at http://www.merck.com/company-overview/leadership/board-of-directors/ (last accessed January 5, 2026)
2411	“Contact us,” MSD, accessible at http://www.msd.com/contact-us/ (last accessed January 5, 2026)
2412	“Contact us,” Merck, accessible at http://www.merck.com/contact-us/ (last accessed January 5, 2026)
2413	“Who we are,” MSD, accessible at http://www.msd.com/company-overview/ (last accessed January 5, 2026)
2414	“Who we are,” Merck, accessible at http://www.merck.com/company-overview/ (last accessed January 5, 2026)

Exhibit No.	Description
2415	Merck & Co., Inc. Form 10-K, Securities and Exchange Commission, February 25, 2025
2416	USPTO OED Practitioner Search - Mark J. Stewart
2417	Petition for <i>Inter Partes</i> Review, <i>Merck Sharp & Dohme LLC v. The Johns Hopkins University</i> , IPR2024-00240 (P.T.A.B.), November 30, 2023
2418	Petition for <i>Inter Partes</i> Review, <i>Merck Sharp & Dohme LLC v. The Johns Hopkins University</i> , IPR2024-00622 (P.T.A.B.), March 4, 2024
2419	Petition for <i>Inter Partes</i> Review, <i>Merck Sharp & Dohme LLC v. The Johns Hopkins University</i> , IPR2024-00623 (P.T.A.B.), March 4, 2024
2420	Petition for <i>Inter Partes</i> Review, <i>Merck Sharp & Dohme LLC v. The Johns Hopkins University</i> , IPR2024-00624 (P.T.A.B.), March 4, 2024
2421	Petition for <i>Inter Partes</i> Review, <i>Merck Sharp & Dohme LLC v. The Johns Hopkins University</i> , IPR2024-00625 (P.T.A.B.), March 4, 2024
2422	Petition for <i>Inter Partes</i> Review, <i>Merck Sharp & Dohme LLC v. The Johns Hopkins University</i> , IPR2024-00647 (P.T.A.B.), March 13, 2024
2423	Petition for <i>Inter Partes</i> Review, <i>Merck Sharp & Dohme LLC v. The Johns Hopkins University</i> , IPR2024-00648 (P.T.A.B.), March 13, 2024
2424	Petition for <i>Inter Partes</i> Review, <i>Merck Sharp & Dohme LLC v. The Johns Hopkins University</i> , IPR2024-00649 (P.T.A.B.), March 13, 2024

Exhibit No.	Description
2425	Petition for <i>Inter Partes</i> Review, <i>Merck Sharp & Dohme LLC v. The Johns Hopkins University</i> , IPR2024-00650 (P.T.A.B.), March 13, 2024
2426	MERCK_PGR00035 - 20250813 Payment Remittance_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2427	MERCK_PGR00042 - Dechert T360 Halozyme - 202500327_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2428	MERCK_PGR00045 - FW_Atnn_Accounts Receivable Dept - PAYMENT REMITTANCE DETAIL (Nov 2025)_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2429	MERCK_PGR00049 - Halozyme - 202000447 - Invoices 5_1_2024-12_22_2025_1 of 3_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2430	MERCK_PGR00465 - Mark Stewart Payroll Statement for Dec 12 2025_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2431	MERCK_PGR00001 - Workday - Ginkel Organization Screen Shot (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2432	MERCK_PGR00002 - Workday - Lally Organization Screen Shot (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2433	MERCK_PGR00003 - Workday - Majchrzak Organization Screen Shot (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2434	MERCK_PGR00004 - Workday - Stewart Organization Screen Shot (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2435	MERCK_PGR00005 - Workday - Su Organization Screen Shot (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)

Exhibit No.	Description
2436	MERCK_PGR00036 - 20250903 Payment Remittance_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2437	MERCK_PGR00037 - 20251001 Payment Remittance_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2438	MERCK_PGR00038 - 20251203 Payment Remittance_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2439	MERCK_PGR00040 - 20251215 Payment Remittance_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2440	MERCK_PGR00046 - FW_Atn_Accounts Receivable Dept - PAYMENT REMITTANCE DETAIL (Oct 2025)_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2441	MERCK_PGR00047 - FW_Atn_Accounts Receivable Dept - PAYMENT REMITTANCE DETAIL (Sept 2025)_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2442	MERCK_PGR00048 - Halozyme - 202000447 - Invoice IN00125072310 Review History (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2443	MERCK_PGR00050 - Halozyme - 202000447 - Invoices 5_1_2024-12_22_2025_2 of 3_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2444	MERCK_PGR00051 - Halozyme - 202000447 - Invoices 5_1_2024-12_22_2025_3 of 3_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2445	By-Laws of Merck & Co., Inc., Effective as of November 19, 2024

TABLE OF AUTHORITIES

Cases

<i>AbbVie Deutschland GmbH & Co., KG v. Janssen Biotech, Inc.</i> , 759 F.3d 1285 (Fed. Cir. 2014).....	4, 41, 50
<i>Ajinomoto Co., Inc. v. International Trade Commission</i> , 932 F.3d 1342 (Fed. Cir. 2019).....	33, 41
<i>Alnylam Pharms., Inc. v. Moderna, Inc.</i> , 138 F.4th 1326 (Fed. Cir. 2025)	30
<i>Amgen Inc. v. Sanofi</i> , 598 U.S. 594 (2023).....	6, 53
<i>Ariad Pharms., Inc. v. Eli Lilly & Co.</i> , 598 F.3d 1336 (Fed. Cir. 2010).....	passim
<i>armaceutical Resources, Inc. v. Roxane Laboratories, Inc.</i> , 253 F. App'x 26 (Fed. Cir. 2007)	62
<i>Atlas Powder Co. v. E.I. Dupont De Nemours</i> , 750 F.2d 1569 (Fed. Cir. 1984).....	62
<i>Capon v. Eshhar</i> , 418 F.3d 1349 (Fed. Cir. 2005).....	48
<i>Constant v. Advanced Micro-Devices, Inc.</i> , 848 F.2d 1560 (Fed. Cir. 1988).....	32
<i>Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., Ltd.</i> , 535 U.S. 722 (2002).....	6
<i>Idenix Pharm. LLC v. Gilead Sci. Inc.</i> , 941 F.3d 1149 (Fed. Cir. 2019).....	51
<i>Immunex Corp. v. Sandoz Inc.</i> , 964 F.3d 1049 (Fed. Cir. 2020).....	48
<i>In re Ruschig</i> , 379 F.2d 990 (C.C.P.A. 1967)	41
<i>In re Wands</i> , 858 F.2d 731 (Fed. Cir. 1988).....	51
<i>Kyocera Senco Industrial Tools Inc. v. ITC</i> , 22 F.4th 1369 (Fed. Cir. 2022)	30

<i>ParkerVision v. Vidal</i> , 88 F.4th 969 (Fed. Cir. 2023).....	30
<i>Phillips v. AWH Corp.</i> , 415 F.3d 1303 (Fed. Cir. 2005).....	29
<i>Reiffin v. Microsoft Corp.</i> , 214 F.3d 1342 (Fed. Cir. 2000).....	8
<i>Teleflex, Inc. v. Ficosa North America Corp.</i> , 299 F.3d 1313 (Fed. Cir. 2002).....	32
<i>Thorner v. Sony Computer Ent Am. LLC</i> , 669 F.3d 1362 (Fed. Cir. 2012).....	29
Statutes	
35 U.S.C. § 112.....	33

I. INTRODUCTION

U.S. Patent No. 12,077,791 (the '791 patent)¹ is directed to a “modified PH20 polypeptide” with a substitution at one specific position in the amino acid sequence of PH20—position 309. Position 309 is an isoleucine (“I”) in the unmodified sequence, and thus the substitution at 309 is referred to as the “I309 mutation” herein. EX1001, cl.1. The claimed substitution must consist of one of ten amino acids—E, G, H, L, M, N, Q, R, S, or T. *Id.* All ten of the recited amino acid substitutions at position 309 improve the activity of the modified PH20 compared to wildtype, with one substitution (N) increasing activity by over 300%. EX1001, Table 9. It is undisputed that these mutations were not known in the art.

The '791 inventors discovered the I309 mutation through an unprecedented comprehensive, and systematic analysis of PH20's structure. The inventors performed this analysis through large-scale mutagenesis and enzymatic activity testing of thousands of variants. EX2068, ¶154; EX2070, ¶44, 233-34. Specifically, among its teachings regarding PH20, the '791 patent provides the results of a mutagenesis experiment in which *every single position* in a mature, soluble, active PH20 (SEQ ID No: 3) was mutated with up to 18 different amino acids and then

¹ Petitioner challenges patentability of claims 1-3 and 6-10 of the '791 patent. Dependent claims 4-5 have been statutorily disclaimed. EX2003.

tested for activity and compared to wildtype. *Id.*

The results of this study detail the common structural elements of active PH20s and their correlation to hyaluronidase function. EX2068, ¶¶154-160; EX2070, ¶¶51-58. Specifically, for the mature, soluble PH20 polypeptide, the study identifies which positions and regions tolerate substitutions and which do not, which types of residues at each position are likely to be successful in terms of maintaining activity,² and which positions in particular could be targeted to maintain or improve activity. *Id.* As the '791 patent³ states, the “[d]etailed **structure/function**⁴ of virtually each amino acid in a PH20 polypeptide is provided herein” along with “the identification of residues and loci that contribute to alteration of a property, such as stability in particular conditions.” EX1001, 3:19-23.

In short, the '791 patent data enabled POSAs to make enzymatically active PH20s with single and multiple mutations because the data showed POSAs where

² Patentee uses the term “activity” throughout as short for hyaluronidase enzymatic activity.

³ There is no dispute that the '791 patent and the U.S. Patent Application No. 13/694,731 (“the '731 application”) share a substantively identical specification. Pet., 6. For convenience, citations are to the disclosure of the '791 patent.

⁴ Emphasis has been added throughout, unless otherwise noted.

to make changes, and what types of changes to make. EX2070, ¶¶45-50. As a corollary, it also taught them numerous ways to inactivate PH20.

Based on this expansive body of work—which comprises data for over 5800 variants—the inventors claimed only ten variants. Specifically, the inventors claimed those variants in which the I in wild type at position 309 is replaced with an E, G, H, L, M, N, Q, R, S, or T ”I309E,” “I309G,” “I309H,” “I309L,” “I309M,” “I309N,” “I309Q,” “I309R,” “I309S,” and “I309T”). And, commensurate with the scope of their mutagenesis study, the inventors also claimed subvariants with at least 95% identical primary structure to the ten novel variants. EX2068, ¶¶254, 260-268, EX2070, ¶¶239-43, 389.

As a result, the claimed genus is extremely narrow. The inventors did not claim, for example, all modified polypeptides that degrade hyaluronan; they did not even claim all modified *PH20s* that degrade hyaluronan; nor even the full set of modified PH20 polypeptides that have a substitution at position 309. They instead claimed a highly limited genus.

Additionally, as Patentee’s experts, Drs. Simpson and Petsko, explain, within this narrow genus, the claimed proteins are structurally homogeneous in that they share at least 95% identical primary structure, the I309 mutation, and for those that are active, the same PH20 tertiary structure, including several common structural features (including a common active site). EX2068, ¶¶29, 253-320; EX2070, ¶¶389-

426. And POSAs would have understood the inventors' work, including their comprehensive characterization of PH20's structure from end-to-end, to provide a detailed specification of the correlations between the structure of PH20 and its hyaluronidase function. This characterization allows POSAs to predictably distinguish between and make and use the full scope of the modified PH20s within the scope of the claim. *Id.* That is sufficient for written description and enablement.

Petitioner's written description and enablement challenges are premised on its characterization of claimed genus as having "extreme breadth." Pet., 2. Petitioner uses the math of permutations like a parlor trick, focusing on pure numbers, to distract from the fundamental fact that the scope of the claims is confined to the ten I309 variants and 95% identical subvariants.

In particular, Petitioner relies on cases like *Ariad*, *AbbVie*, and others, which involved both a structurally diverse genus and claims that recited "a description of the problem to be solved while claiming all solutions to it [via].... functional boundaries." *Ariad Pharms., Inc. v. Eli Lilly & Co.*, 598 F.3d 1336, 1353 (Fed. Cir. 2010). But unlike those cases, the patent claims do not "claim[] all solutions." Not even close. The claims cover not even a miniscule fraction of all of the proteins that cleave HA (or even all of the PH20s that cleave HA). EX2068, ¶¶260-268. Indeed, all one need to do to avoid the claims is not practice the 309 mutation that the Halozyme inventors indisputably were the first to identify. Or, using the data in the

patent itself, mutate the primary structure slightly more than 5%. Given the lack of structural diversity in the genus (EX2068, ¶¶351-356), a patent monopoly could hardly be more limited.

In fact, as explained in depth below as to written description (Ground 1), by limiting the claims to ten variants with the I309 mutation and the subvariants to 95% structural identity, the inventors ensured the active PH20s within the genus, including those with single and multiple mutations, share the same common mechanism of action and common PH20 tertiary structure, including the common active site and supporting “scaffolding” of disulfide bridges and other features necessary to activity. EX2068, ¶¶270-287, 292; EX2070, ¶¶389-426. Moreover, the specification teaches a POSA how to reasonably and reliably distinguish those PH20s that will be inactive. *Id.*

As to enablement (Ground 2), Patentee in no way left the invention “unfinished,” as Petitioner contends. *Ariad*, 598 F.3d at 1353. Petitioner characterizes the inventors’ work—a comprehensive characterization of *every* position in the tested PH20 sequence—as effectively useless. According to Petitioner, the inventors left to others only a so-called “research plan” (Pet., 32). But that makes no sense. The inventors did the work to identify the I309 mutation and provided—via a detailed and thorough analysis of over 5800 different PH20 polypeptide mutants—a comprehensive correlation between PH20’s structure and

its activity—i.e. “some general quality... running through the class that gives it a peculiar fitness for the particular purpose.” *Amgen Inc. v. Sanofi*, 598 U.S. 594, 611 (2023).

All POSAs need to do is follow the inventor’s guidance to practice the claim. It is trivial to introduce the I309 mutation into PH20—the heart of the claimed invention; beyond what is provided in the specification, it takes no research at all. And POSAs can readily identify other positions to change should they wish, using the comprehensive structure-function data provided in the specification. EX2070, ¶¶276-91. The inventors’ work allows POSAs to easily and predictably practice additional mutations or other variants with only ordinary skill. EX2068, ¶¶343-347.

Inventors “rely on the promise of the law to bring the invention forth,” describing the invention in the specification in exchange for the limited monopoly granted by the claims. *Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., Ltd.*, 535 U.S. 722, 730-31 (2002). As part of this bargain, as explained in *Ariad*, “the scope of the right to exclude... [must] not overreach the scope of the inventor’s contribution to the field of art as described in the patent specification.” *Ariad*, 598 F.3d at 1353–54 (internal quotation marks omitted). Here, the inventors in no way overreached in exchange for their expansive disclosure; they sought and received highly limited claims to a structurally homogeneous set of modified PH20s that require a single amino acid mutation at a single position that is trivially avoided

unless one is looking over the inventor's shoulders, copying their work. They described, in full, the results of their work in exchange for a limited, time-bound monopoly, allowing others to practice the invention when the claims expire. The work they disclosed is sufficient for written description and enablement. They deserve the full "promise of the law"—the protection granted by the claims.

As set out further below, Patentee requests that the Board find all the challenged claims patentable as to each of Grounds 1-2.

II. BACKGROUND

A. Patentee's Experts

Because Patentee refers to the work of its experts throughout the sections below, Patentee briefly summarizes their background:

Dr. Melanie Simpson is the Head of the Department of Molecular and Structural Biochemistry at North Carolina State University. She is also the Director of Research of the Integrative Sciences Initiative at North Carolina State University, Raleigh, NC. And she serves as the President of the International Society for Hyaluronan Sciences ("ISHAS"). She has extensive practical experience researching hyaluronidases, which have been a focus of her research since 1998, including work that is among the key hyaluronidase mutagenesis studies in the field. EX2068, ¶¶9-20.

Dr. Gregory Petsko is a distinguished American biochemist and structural

biologist known for his pioneering work in protein crystallography and enzyme mechanisms. He is renowned for his research on protein structure-function relationships, including the use of techniques such as X-ray crystallography and computational modeling. He is a National Medal of Science winner. He is currently Professor of Neurology at the Ann Romney Center for Neurologic Diseases at Harvard Medical School and Brigham and Women's Hospital. EX2070, ¶¶1-23.⁵

B. Technical Background

Patentee briefly summarizes the art as of December 28, 2012⁶ regarding the structure of hyaluronidases, their mechanism of action and the amino acids known to be important for activity.

PH20 is a member of a class of enzymes called hyaluronidases. PH20 occurs on the sperm surface. EX1001, 44:1-37. As a hyaluronidase, PH20 cleaves hyaluronan (“HA”), which is a linear, negatively charged glycosaminoglycan made of repeating disaccharide units. EX1006 (Chao), 6911. There are five human

⁵ Patentee withdraws the testimony of Dr. Triggs-Raine (EX2001).

⁶ Patentee applies the December 28, 2012 filing date of the '731 application for purposes of responding to Petitioner's written description and enablement challenges (Grounds I–II). *Reiffin v. Microsoft Corp.*, 214 F.3d 1342, 1345 (Fed. Cir. 2000); *Ariad*, 598 F.3d at 1353-54.

hyaluronidases, three of which are known to degrade HA: PH20, Hyal-1, and Hyal-


2. *Id.* HA-degrading enzymes also occur in other organisms, including bees (bee venom hyaluronidase helps a bee spread venom from a sting).

By 2012, the crystal structures for bee venom hyaluronidase (EX1033) and human Hyal-1 (EX1006) had been solved. It is not disputed that based on these solved structures, a POSA's knowledge included possession of an accurate homology model of PH20; both Petitioner and Patentee rely on such a model here. As Petitioner's expert testified, "In the year 2011, to consider a mutation, it would have been very common and expected for POSAs to generate a model and consider the substitution in that structural context." EX2077, 176:2-5; EX2076, 92:22-94:22.⁷

Dr. Petsko provides a detailed summary of a POSA's knowledge of PH20, Hyal-1, and bee venom hyaluronidase, detailing a POSA's knowledge of the critical common features even though these hyaluronidases share only 30-40% sequence identity. EX2070, ¶¶126-213, 112-125, 59-111; EX1006, 6912; EX1008, 826; *see also* EX1004 (Park), ¶¶ 40, 141; EX2077, 93:9-94:8.

⁷ The parties have stipulated that the deposition testimony from both Petitioner's and Patentee's witnesses in related PGRs PGR2025-00003, -00004, -00006, and -00009 can be applied here.

In sum, these hyaluronidases all share a tertiary structure a POSA would recognize as an “alpha-beta barrel fold.” Their nearly identical tertiary structures are depicted below:




EX2070, ¶¶129-134.

As Drs. Petsko and Simpson explain, POSAs knew that PH20s (as well as Hyal-1 and bee venom hyaluronidase) share a common mechanism of action in that they all cleave HA through the same chemical reaction (EX1010, 9433 EX2092; EX2070, ¶¶135-38), via a common structure—the active site in all three proteins, which contains critical residues oriented in about the same position (EX1008, 833; EX1033, 1028; EX2070, ¶¶139-44). *See generally* EX1006 (reporting as to Hyal-1,

bee venom hyaluronidase “that the active site clefts are similar in size and shape”); EX1006 (Chao), 6914 (“the active site of hHyal-1 spans an elongated cleft”); EX2070, ¶¶139-44 (showing common elongated cleft/groove on PH20 model); EX2068, ¶¶280-283.

Despite the substantial difference in sequence (60-70%), the critical active site residues in Hyal-1, bee venom hyaluronidase and PH20 are also conserved in terms of their identity, their positioning, and their interactions with HA, as illustrated by Dr. Petsko’s analysis in which superimposes and examines the structures. A representative figure below shows the PH20 model superimposed on the Hyal-1 structure and the bee venom structure and illustrates the overlapping primary, secondary and tertiary structural features, including common structural features down to the atomic level, with dotted lines illustrating the overlap between interactions:



EX2070, ¶157.

Those working in the field at the time, including Dr. Simpson, had also conducted some limited mutagenesis experiments to determine the importance of certain Hyal-1 and PH20 residues for enzymatic activity, using the data to draw conclusions on the role of a set of tested residues, including their criticality to the active site and stability. *see also* EX1010, EX2011; EX1033, 1029; EX2070, ¶¶207-30, 297-342; EX2068 ¶¶134-153. It was thus routine in the field to use such data to illuminate common structures.

C. The '791 Patent

The '791 patent discloses a comprehensive and systematic analysis of each and every position within the primary structure of PH20 (SEQ ID No: 3), which the inventors performed through large-scale mutagenesis and enzymatic activity testing of over 5800 variants. EX2068 ¶154; EX2070, ¶¶57, 231-38. The patent also discloses significant additional teachings regarding PH20, including other PH20 mutagenesis studies and studies regarding the effect of serial C-terminal truncations (conducted by some of the inventors), among others, as set out in this section and Sections II.B and II.C.5 below.

Based on the structure/function data provided via the assays described in Examples 2-4, the '791 patent teaches “modified PH20 polypeptides” that “exhibit altered activities or properties compared to a wildtype, native or reference PH20 polypeptide.” EX1001, 73:62-64. In particular, the patent teaches that the disclosed

modified PH20 polypeptides include those that are active variants, inactive variants, and variants with increased stability. *Id.*, 73:64-74:8. Among these variants, the inventors identified numerous substitutions that increase enzymatic activity, including the ten substitutions at position 309 recited in the claims. EX1001, Table 9.

As Drs. Simpson and Petsko explain, POSAs would have understood this data as useful far beyond identifying individual mutations; considered as a whole, the inventors' work provides a detailed specification of the structure/function correlations in PH20 that identifies for POSAs the extent to which each position in the sequence tolerates substitutions and which do not, which types of residues at each position are likely to be successful in terms of maintaining activity, and which positions in particular could be targeted to maintain or improve (or reduce or abrogate) activity. EX2068 ¶¶154-160, 244-245, 312, 320, 370-372, 376-381; EX2070, ¶¶248-342. As the '791 patent states, the "[d]etailed structure/function of virtually each amino acid in a PH20 polypeptide is provided herein" along with "the identification of residues and loci that contribute to alteration of a property, such as stability in particular conditions." EX1001, 3:19-23.

As both Drs. Simpson and Petsko confirm, this level of structure/function detail for an individual protein of this size was virtually unheard of as of 2012, and outside of the patent's disclosure, remains so, at least in the public domain. EX2070,

¶¶233-34; EX2068, ¶¶159-160. Neither are aware of a comparable project, and the data is extraordinarily useful to POSAs in understanding the invention and seeking to practice the claims. *Id.*

Key sequences referred to in the claims and specification are identified below in Section II.C. Key portions of the inventors' study are also described below in Sections II.C.2-3.

In short, the key examples and tables are as follows:

- Example 2 discloses the generation of the PH20 variant library used in the experiment. EX1001, 199:10-229:56.
 - Table 8 provides a list of the mutations used to prepare the library. EX1001, 200:36-229:32.
- The test methods for the activity assays are described in Example 3. EX1001, 229:59-232:37.
- The results of the activity assays are provided in Example 4.
 - Table 9 identifies the “active” variants for which at least one of the two samples tested exhibited greater than 40% of wildtype (SEQ ID NO: 3) activity, along with corresponding activity data. EX1001, 234:7-255:39. The patent also lists the residues at each position that resulted in active PH20s in Table 3. *Id.*, 80:20-87:59.
 - Table 10 provides confirmed inactive mutants, which achieved

less than 20% of wildtype activity. EX1001, 256:58-267:25. The patent also provides the residues at each position that resulted in less than 20% activity in Table 5. *Id.*, 119:1-129:10.

To facilitate consideration of this data in a consolidated format, Dr. Petsko provides a spreadsheet with data imported from Tables 3, 5, 9 and 10 into Excel so that the data could be color coded and sorted. EX2070, ¶¶263-74.

The patent also discloses general teachings regarding the structures common to the active PH20s that are confirmed or further refined by the mutagenesis data, as further discussed below.

1. Key Sequences Referred to in the Patent

The '791 patent provides the following exemplary sequences:

- **SEQ ID NOs: 6 and 7:** SEQ ID NO: 6 is a full length “precursor” PH20 consisting of 509 amino acids, including a 35 amino acid signal sequence. SEQ ID NO: 7 is the “mature” version, without the 35 amino acid signal sequence (474 amino acids).
- **SEQ ID NO: 3:** A mature, soluble, C-terminally truncated PH20 used as the control in the '791 patent. The PH20 in SEQ ID NO: 3 lacks the signal sequence is also C-terminally truncated by 27 amino acids. It thus consists of 447 amino acids, each of which was varied in the patent’s mutagenesis study. The inventors refer to this version as “wild type” in the patent.

- **SEQ ID NOs: 32-66:** These sequences are other C-terminal truncation variants of PH20 disclosed in the specification. Like SEQ ID NO: 3, they lack the signal sequence. They serially increase in length by one amino acid from SEQ ID NO: 32 (430 amino acids) to SEQ ID NO: 66 (465 amino acids). SEQ ID NO: 35, recited in claim 1 of the '791 patent, comprises 433 amino acids. Halozyme's prior work studying C-terminal truncations, discussed below in Section II.C.5, involved testing these truncations and would have taught POSAs their expected effect on activity.

See generally EX2068, ¶¶161-171.

2. Example 2

Example 2 of the patent describes the creation of a mutagenesis library in which a mature, soluble, active PH20 sequence (SEQ ID NO: 3) was systematically mutated at each of its 447 residues by substituting at least one and up to 18 different amino acids. EX1001, 199:10-229:56. Results are provided for, on average, 13 substitutions at each position. EX2068, ¶192; EX2070, ¶¶264-273. Table 8 provides the resulting set of 6753 modified PH20 polypeptides. EX1001, 200:36-229:32.

The specification describes the inventors' experiment, which involved the design of an expression vector for each variant, along with secreted alkaline phosphatase (SEAP), under a single promoter. This elegant design allowed the inventors to track expression levels (by tracking the amount of SEAP) in order to

normalize the results of the activity assay, to account for differences in both transfection and expression levels for each variant. *Id.* at 199:10-229:56, 232:41-233:2; EX2068, ¶¶197-199.

3. Examples 3 & 4

Examples 3 and 4 describe the development and results of a comprehensive activity assay, cataloging the effect of mutations made at each of the 447 residues of a mature, soluble PH20 sequence (SEQ ID NO: 3).

The inventors assessed the hyaluronidase activity of each variant using an ELISA assay (described in Example 3). In brief, the inventors generated biotinylated hyaluronic acid (“bHA”) substrate, which was bound to plates, and then incubated with variant or wild type PH20, allowing the PH20s to degrade the bound bHA substrate (if active). EX1001, 229:59-232:37; EX2068, ¶¶193-196. Ultimately, the inventors measured the optical density, which correlates to the amount of bHA remaining on the plate, and compared the results to the average activity obtained for of wild-type PH20 (SEQ ID NO: 3) on the same plate. EX2068, ¶¶193-196. The results show the extent to which the substitution impacted HA activity. *Id.*

a. Data on Active Mutants

Using the methods described above, the inventors collected and presented comprehensive activity data for up to 18 substitutions (on average 13 substitutions) at every single one of the 447 positions in the mature PH20 sequence (SEQ ID NO:

3). Each position was changed to a range of amino acids with a wide range of properties (*i.e.*, large, small, hydrophobic, hydrophilic, charged, not charged), and the effect on enzymatic activity was determined. EX2070, ¶¶54, 254-261. This was not a random mutagenesis experiment disclosing the results of a handful of single point mutations in scattered portions of the protein. This was a systematic structure-function mapping exercise that discloses the tolerance of every single position to substitution.

The inventors identified 2527 active variants, which are provided in Table 9. Specifically, Table 9 provides “the average hyaluronidase activity of tested duplicates normalized by SEAP values compared to average of wildtype PH20 activities in each plate, which were also normalized by their own SEAP values.” *Id.*, 232:50-61.⁸ “For example, a value of 0.40 indicates that the variant exhibits 40% of the hyaluronidase activity of wildtype PH20, a value of 1 indicates that the variant exhibits a similar hyaluronidase activity of wildtype and a value of 3.00 indicates that the variant exhibits 300% of the hyaluronidase activity of wildtype PH20 or 3-

⁸ As Dr. Simpson explains, there are variants in Table 9 with activity values less than 40% of wild type because one of two samples exhibited an activity greater than 40% of wild type, and the value presented is the average obtained for the two samples.

fold increased activity compared to wildtype.” *Id.*, 232:61-67.

“The results in Table 9 show that over 600 tested mutants exhibit activity that is increased compared to wildtype. For example, about 536 mutants exhibit 120% or greater than 120% of the hyaluronidase activity of wildtype PH20 and about 75 of the mutants exhibit 300% or greater than 300% of the hyaluronidase activity of wildtype PH20.” *Id.*, 233:1-6.

Collectively, at least one amino acid change made in 352 different positions in PH20 generated active polypeptides. EX1001, Table 9; EX2068, ¶¶201; EX2070, ¶¶254-61. As Drs. Petsko and Simpson show, and as is discussed further below, POSAs would have understood the collective data to demonstrate areas and positions within the PH20 structure that are highly tolerant or intolerant to change and to identify particularly beneficial substitutions. EX2070, ¶¶262, 275-96, 317-42; EX2068, ¶¶345.

b. The I309 Mutation

Some of the disclosed variants exhibited highly significant changes in activity relative to wildtype. For instance, the inventors disclosed fifteen modified amino acids at amino acid residue number I309, including E, G, H, L, M, N, Q, R, S, and T. *See* Patent Table 8. Fourteen of the modifications at residue I309 produced enzymatically active PH20s, and ten resulted in increased activity—E, G, H, L, M, N, Q, R, S, and T. *See* Patent Table 3; Table 9. The substitution to asparagine (N)

provided the greatest improvement in activity—311% compared to wild-type. *Id.*

c. Data on Inactive Mutants

The patent also provides extensive data regarding mutations that were *not tolerated* in terms of enzymatic activity—i.e., mutations that reduced hyaluronidase activity to below 20% of wildtype activity. The inventors identified the inactive mutants through initial screening in Example 3.

Then, the inventors rescreened these mutants in a “modified assay” involving a longer incubation time that was “intended to detect PH20 activities below 0.2 U/mL.” EX1001, 255:49-51. Specifically, mutants that “exhibited less than 20% hyaluronidase activity of wildtype PH20, in at least one of the duplicates, were rescreened to confirm that the dead mutants are inactive.” *Id.*, 255:43-46. Table 10 provides the “reconfirmed inactive mutants,” which again are those that achieved less than 20% of wildtype activity. *Id.*, 256:53-54.

Table 10 discloses 3320 inactive PH20s. Table 10 shows that at least one amino acid change made in 407 different positions in PH20 generated inactive polypeptides. EX1001, Table 10; EX2068, ¶207; EX2070, ¶260. As with the actives data, POSAs would have understood the collective inactives data to provide further guidance on modifying PH20s, demonstrating areas and positions within of the PH20 structure that are intolerant to change or that only tolerate limited substitutions. EX2070, ¶¶292-296; EX2068, ¶¶301-312, 377.

d. Tolerability at Each Position Based on Enzymatic Activity Testing

Dr. Petsko illustrates the patent's teaching regarding tolerability to change within PH20's structure by copying the patent data into a spreadsheet and then color coding the 447 positions based on their tolerability to substitution, showing how POSAs would understand the data. That illustration is reproduced below:

		30 D	61 L	92 A	123 W	154 K	185 L
Position	WT	31 E	62 G	93 K	124 K	155 Q	186 F
1	L	32 P	63 Y	94 K	125 P	156 E	187 P
2	N	33 L	64 Y	95 D	126 K	157 F	188 D
3	F	34 D	65 P	96 I	127 D	158 E	189 C
4	R	35 M	66 Y	97 T	128 V	159 K	190 Y
5	A	36 S	67 I	98 F	129 Y	160 A	191 N
6	P	37 L	68 D	99 Y	130 K	161 G	192 H
7	P	38 F	69 S	100 M	131 N	162 K	193 H
8	V	39 S	70 I	101 P	132 R	163 D	194 Y
9	I	40 F	71 T	102 V	133 S	164 F	195 K
10	P	41 I	72 G	103 D	134 I	165 L	196 K
11	N	42 G	73 V	104 N	135 E	166 V	197 P
12	V	43 S	74 T	105 L	136 L	167 E	198 G
13	P	44 P	75 V	106 G	137 V	168 T	199 Y
14	F	45 R	76 N	107 M	138 Q	169 I	200 N
15	L	46 I	77 G	108 A	139 Q	170 K	201 G
16	W	47 N	78 G	109 V	140 Q	171 L	202 S
17	A	48 A	79 I	110 I	141 N	172 G	203 C
18	W	49 T	80 P	111 D	142 V	173 K	204 F
19	N	50 G	81 Q	112 W	143 Q	174 L	205 N
20	A	51 Q	82 K	113 E	144 L	175 L	206 V
21	P	52 G	83 I	114 E	145 S	176 R	207 E
22	S	53 V	84 S	115 W	146 L	177 P	208 I
23	E	54 T	85 L	116 R	147 T	178 N	209 K
24	F	55 I	86 Q	117 P	148 E	179 H	210 R
25	C	56 F	87 D	118 T	149 A	180 L	211 N
26	L	57 Y	88 H	119 W	150 T	181 W	212 D
27	G	58 V	89 L	120 A	151 E	182 G	213 D
28	K	59 D	90 D	121 R	152 K	183 Y	214 L
29	F	60 R	91 K	122 N	153 A	184 Y	215 S

216 W	247 V	278 L	309 I	340 M	371 A	402 C	433 F
217 L	248 R	279 K	310 M	341 C	372 I	403 Y	434 L
218 W	249 E	280 F	311 R	342 S	373 Q	404 S	435 K
219 N	250 A	281 L	312 S	343 Q	374 L	405 T	436 P
220 E	251 I	282 S	313 M	344 V	375 E	406 L	437 P
221 S	252 R	283 Q	314 K	345 L	376 K	407 S	438 M
222 T	253 V	284 D	315 S	346 C	377 G	408 C	439 E
223 A	254 S	285 E	316 C	347 Q	378 G	409 K	440 T
224 L	255 K	286 L	317 L	348 E	379 K	410 E	441 E
225 Y	256 I	287 V	318 L	349 Q	380 F	411 K	442 E
226 P	257 P	288 Y	319 L	350 G	381 T	412 A	443 P
227 S	258 D	289 T	320 D	351 V	382 V	413 D	444 Q
228 I	259 A	290 F	321 N	352 C	383 R	414 V	445 I
229 Y	260 K	291 G	322 Y	353 I	384 G	415 K	446 F
230 L	261 S	292 E	323 M	354 R	385 K	416 D	447 Y
231 N	262 P	293 T	324 E	355 K	386 P	417 T	
232 T	263 L	294 V	325 T	356 N	387 T	418 D	
233 Q	264 P	295 A	326 I	357 W	388 L	419 A	
234 Q	265 V	296 L	327 L	358 N	389 E	420 V	
235 S	266 F	297 G	328 N	359 S	390 D	421 D	
236 P	267 A	298 A	329 P	360 S	391 L	422 V	
237 V	268 Y	299 S	330 Y	361 D	392 E	423 C	
238 A	269 T	300 G	331 I	362 Y	393 Q	424 I	
239 A	270 R	301 I	332 I	363 L	394 F	425 A	
240 T	271 I	302 V	333 N	364 H	395 S	426 D	
241 L	272 V	303 I	334 V	365 L	396 E	427 G	
242 Y	273 F	304 W	335 T	366 N	397 K	428 V	
243 V	274 T	305 G	336 L	367 P	398 F	429 C	
244 R	275 D	306 T	337 A	368 D	399 Y	430 I	
245 N	276 Q	307 L	338 A	369 N	400 C	431 D	
246 R	277 V	308 S	339 K	370 F	401 S	432 A	

EX2070, ¶274.

As Dr. Petsko explains, those positions for which all tested substitutions are tolerated are colored green, and those for which no substitutions were tolerated are colored red. Positions for which 60% or more of the substitutions tested were tolerated are colored light green. EX2070, ¶¶263-274. Positions for which 30% or fewer of the substitutions were tolerated are colored orange. *Id.* Residues not colored were those that tolerated more than 30% but less than 60% of the tested substitutions.

Id.

The patent data shows that:

- 158 positions (35%) tolerated 60% or more of the tested substitutions, with 40 positions (9%) tolerating all tested substitutions;
- 214 positions (48%) tolerate 30% or fewer of the tested substitutions, and 95 positions of the 447 (21%) did not tolerate any tested substitutions.

EX2070, ¶¶264-268.

As Dr. Petsko and Dr. Simpson testify, this data is extremely useful to POSAs, because it teaches POSAs what changes can be made in what position(s) to maintain activity (or to abrogate activity). EX2070, ¶¶254-388; EX2068, ¶¶243-245, 369-381.

4. The Patent's Detailed Structure-Function Mapping Significantly Expands The POSA's Knowledge Regarding PH20 Residues Critical for Enzymatic Function

The patent's mutagenesis data also confirms and builds on the summary it provides of residues in PH20 that POSAs knew were important for activity, identifying critical PH20 residues and common structures for active and inactive PH20s alike, including expanding the list of critical residues that, when mutated individually and without potential compensatory mutations, inactivate the protein.

For example, the '791 patent notes the following residues that were identified in the art as either part of the active site or otherwise important for activity: D111,

E113, R176, R246, E249 and R252. EX1001, 68:51-62. Similarly, the patent explains that “PH20 hyaluronidases contain 12 conserved cysteine residues, corresponding to amino acid residue 25, 189, 203, 316, 341, 346, 352, 400, 402, 408, 423 and 429 of the sequence of amino acids of a mature PH20 lacking the signal sequence such as set forth in SEQ ID NO: 3 or 7.” EX1001, 68:31-36; EX2068, ¶291. The patent further discloses that these cysteine residues “form disulfide bridges,” which are involved in “posttranslational protein maturation and/or in activity modulation.” EX1001, 68:38-43; EX2068, ¶291. The patent’s mutagenesis data confirms that active PH20 does not tolerate substitutions at positions 25, 111, 113, 176, 189, 203, 246, 249, 252, 316, 341, 346, 352, 400, 402, 408, 423 and 429, with two exceptions. EX1001, 68:63-69:4; EX2068, ¶291. The patent refines the knowledge regarding those positions in that it teaches that C316D and R176K produced variants with some activity, a result POSAs would not have expected. EX2070, ¶¶275, 314-16, 333.

The patent also recognizes the prior art teaching that “[g]lycosylation also is required for PH20 hyaluronidase activity,” and in particular, “at least N-linked glycosylation sites corresponding to amino acid residues N200, N333 and N358 are required for secretion and/or activity of the enzyme.” EX1001, 69:7-8, 14-17. “For example...amino acid mutations N200A, N333A, N358A or N333A/N393A” produce “inactive proteins.” *Id.*, 69:18-20. By contrast, “[s]ingle mutations of

glycosylation sites N47A, N131A, N219A, N47A/N131A, N47A/N219A, N131A/N219A retain activity.” *Id.*, 69:20-22. At the same time, the patent expands on the knowledge regarding these positions, teaching that limited modifications at positions N200 and N358 produced variants with some activity. EX2070, ¶¶214-17, 252.

5. C-Terminal Truncations

The patent also teaches that wildtype PH20 “contain[s] a glycosyl phosphatidylinositol (GPI) anchor attached to the C-terminus of the protein,” and that “removal of all or a portion of the GPI anchor attachment signal site” can generate “soluble” forms of the PH20 protein that are secreted from the cell. EX1001, 69:46-61. The patent explains that the secreted “soluble” modified PH20 polypeptides include “soluble PH20 polypeptides set forth in any of SEQ ID NOs: 3 or 32-66, or precursor forms thereof containing a signal sequence.” EX1001, 69:62-65.

As Dr. Simpson explains, the soluble polypeptides in SEQ ID NOs: 3 and 32-66 each begin at position 36 of the precursor PH20 sequence (*i.e.* the sequence with the 35 amino acid signal peptide), and differ from each other only at the C-terminus, where they reflect a series of single amino acid truncations. The first 430 residues of these 35 sequences are identical. Starting with position 430 (SEQ ID NO: 32), each sequence successively adds a single residue up through position 465 (SEQ ID NO:

66). SEQ ID NO: 3, the control for the patent's mutagenesis experiments, is 447 amino acids in length. EX2068, ¶¶168-169, 190; EX2006, 2, 15-26.

The '457 publication, which is incorporated by reference into '791 patent, teaches which of these C-terminal truncation variants are active and which are not. Dr. Petsko provides a table in his declaration showing the activity profile of each of SEQ ID NOs: 3 and 32-66, based on this data. EX2070, ¶385. A simplified version of that table is reproduced below:

SEQ ID NO.	Effect of Truncation on Activity Level
32-33	Inactive
34-35	Reduced
36-55 & 3	Active
56-63	Reduced
64-66	Little to no activity

6. Challenged Claims

The '791 patent includes independent claim 1, and dependent claims 2-3 and 6-10, all of which ultimately depend from claim 1.⁹ Claim 1, which is reproduced below, is directed to a set of C-terminal truncated PH20 polypeptides with one of ten potential substitutions at position 309 (for simplicity, Patentee refers to this set of C-terminally truncated polypeptides collectively as "variants"), and a narrow set of subvariants of those modified C-terminal truncation PH20 polypeptides (*i.e.*,

⁹ Dependent claims 4-5 have been statutorily disclaimed. EX2003.

those with 95% sequence identity).

1. A modified PH20 polypeptide comprising an amino acid sequence, wherein:

(a) at least 95% of the residues of the amino acid sequence of the modified PH20 polypeptide are identical to the residues in the amino acid sequence of SEQ ID NO: 35 when the sequence of the modified PH20 polypeptide is aligned at positions corresponding to the sequence set forth in the amino acid sequence of SEQ ID NO: 35 to maximize identical residues, and terminal gaps are treated as non-identical;

(b) the amino acid sequence of the modified PH20 polypeptide comprises an amino acid modification at a position corresponding to position 309 with reference to amino acid positions set forth in the amino acid sequence of SEQ ID NO: 3; and

(c) the modification at position 309 is a replacement selected from among E, G, H, L, M, N, Q, R, S, and T, and

wherein the modified PH20 polypeptide exhibits increased hyaluronidase activity compared to the hyaluronidase activity of the polypeptide of SEQ ID NO: 3, measured under identical conditions.

The issues for all claims are common such that they are addressed together, unless otherwise noted.

III. PERSON OF ORDINARY SKILL IN THE ART

Solely for the purposes of the analysis herein, Patentee applies Petitioner's POSA definition (Pet., 20; EX1003, ¶13), which was addressed in the Institution Decision (ID, 8-9). Petitioner's declarant Dr. Hecht agreed that POSAs under Petitioner's definition "would have been able to speak with someone with hyaluronidase experience as part of a multi-disciplinary team." EX2076, 63:8-64:2.

IV. Claim Construction Issues

In its Institution Decision, the Board preliminarily found that the term "modified PH20 polypeptide" in the claims "encompass[ed] polypeptides with some hyaluronidase activity." ID, 13.

Patentee maintains that the term "modified PH20 polypeptide" as it is defined in the specification encompasses **both** enzymatically active and enzymatically inactive PH20s. However, in view of the '791 claim language, Patentee does not dispute that the '791 patent claims require modified PH20s with at least some hyaluronidase activity. The parties instead dispute whether the term "modified PH20 polypeptide" *as defined in the specification* requires at least 40% hyaluronidase activity.

The terms of a patent claim "are generally given their ordinary and customary

meaning.” *Phillips v. AWH Corp.*, 415 F.3d 1303, 1312 (Fed. Cir. 2005) (en banc).

The Federal Circuit has established, however, that if the patentee “acts as his own lexicographer” then the definition in the specification controls. *Thorner v. Sony Computer Ent Am. LLC*, 669 F.3d 1362, 1365 (Fed. Cir. 2012). “To act as [his] own lexicographer, a patentee must ‘clearly set forth a definition of the disputed claim term,’” and must “‘clearly express an intent’ to redefine the term.” *Id.* (citations omitted).

The patent specification contains a lengthy “Definitions” section (Part A of the Detailed Description) in which it clearly defines “modified PH20 polypeptide.”

The definition is provided in the italicized sentence in the passage below:

As used herein, “modified PH20 polypeptides” or “variant PH20 polypeptide” refers to a PH20 polypeptide that contains at least one amino acid modification, such as at least one amino acid replacement as described herein, in its sequence of amino acids compared to a reference unmodified PH20 polypeptide. A modified PH20 polypeptide can have up to 150 amino acid replacements, so long as the resulting modified PH20 polypeptide exhibits hyaluronidase activity. Typically, a modified PH20 polypeptide contains 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 amino acid replacements. It is understood that a modified PH20 polypeptide also can include any one or more other modifications, in addition to at least one amino acid replacement as described herein.

EX1001, 47:2-18.

The parties agree that the “modified PH20 polypeptide” term is defined in the specification and that the italicized sentence is definitional. EX2076, 178:21-179:10; Pet., 22-23. The parties dispute, however, whether that sentence constitutes the entire definition (as Patentee argues) or whether the following sentence, and other statements teaching that an active polypeptide can have at least 40% activity, are part of the definition, such that the claimed “modified PH20 polypeptide” must have at least 40% hyaluronidase activity.

The Board should find that Patentee’s interpretation is correct, and the definition of “modified PH20 polypeptide” is limited to the first sentence. A statement is definitional if (1) “*the sentence in question* appears under the title ‘Definitions’”; (2) “the term to be defined....is *set off in quotation marks*”; (3) the sentence “uses the term ‘*refers to*’...which generally conveys an intent for that sentence to be definitional”; or (4) “elsewhere in the Definitions section, [the patent used] “non-limiting terms that contrast with the ‘refer to’ language at issue here.” *Alnylam Pharms., Inc. v. Moderna, Inc.*, 138 F.4th 1326, 1333 (Fed. Cir. 2025) (citations omitted); *see also ParkerVision v. Vidal*, 88 F.4th 969, 977 (Fed. Cir. 2023); *Kyocera Senco Industrial Tools Inc. v. ITC*, 22 F.4th 1369, 1378 (Fed. Cir. 2022). The first sentence in the block quote above plainly satisfies these criteria. That sentence, like claim 1’s recitation of the invention, defines the term by reference

to “its sequence of amino acids compared to a reference unmodified PH20 polypeptide.” EX1001, 47:2-18.¹⁰

The definition provided in the first sentence is also consistent with the usage of the term “modified PH20 polypeptide” throughout the specification, which describes the invention by reference to amino acid sequences, regardless of function or whether the modified PH20s are “active” or “inactive.”

If Petitioner were correct and the second sentence also is part of the definition, then the term “modified PH20 polypeptide” as used in the specification would be limited to enzymatically active PH20 polypeptides, which Petitioner argues must have at least 40% activity. But that interpretation contradicts how the term is used in the specification. The specification repeatedly uses the term “modified PH20 polypeptide” to refer to inactive polypeptides. This is abundantly apparent from the outline provided at the start of the Detailed Description (*Id.*, 42:12-43:17), which

¹⁰ With reference to the criteria considered in *Alnylam*, the term appears in the “Definitions” section of the patent (EX1001, 43:19-66:56); the term is set off in quotation marks (*id.*, 47:2); the definition statement uses the phrases “as used herein” and “refers to” (*id.*, 47:2-3); and the remainder of the passage uses non-limiting, permissive language (“can have”) to differentiate it from the actual definition of “modified PH20 polypeptide” (*id.*, 47:8-9). See *Alnylam* at 1333.

lists the topic “Modified PH20 Polypeptides” as Part C, with subsections C.1 and C.2 describing “Active Mutants” and “Inactive Mutants” respectively. POSAs thus could hardly miss that the specification describes both “active” and “inactive” mutants as “modified PH20 polypeptides.” *See, e.g.* EX1001, 77:44-46, 117:42-46 (“[p]rovided herein are *modified PH20 polypeptides ... that exhibit hyaluronidase activity,*” and also “[p]rovided herein are *modified PH20 polypeptides ... that are inactive,* whereby the polypeptides *do not exhibit hyaluronidase activity* or exhibit low or diminished hyaluronidase activity.”).

Petitioner has no basis for reading a 40% activity threshold into the claims via the “modified PH20 polypeptide” term. Dr. Hecht admitted that none of the claim language specifies 40% hyaluronidase activity, and at deposition he was not willing to defend the construction, stating he was “uncomfortable with fixating on that number.” EX2076, 213:1-5, 172:21-173:9. Petitioner improperly imports a specific embodiment (40% activity) from the specification into the claims, which is not permissible under proper claim construction principles. *Teleflex, Inc. v. Ficosa North America Corp.*, 299 F.3d 1313, 1327-1328 (Fed. Cir. 2002); *Constant v. Advanced Micro-Devices, Inc.*, 848 F.2d 1560, 1571 (Fed. Cir. 1988). Indeed, the specification teaches that “[t]he modified PH20 polypeptides provided herein that are *inactive generally exhibit less than 20% ... of the hyaluronidase activity of a wildtype or reference PH20 polypeptide.*” EX1001, 117:46-49, 255:43-46; Pet., 26-27.

V. THE SPECIFICATION PROVIDES WRITTEN DESCRIPTION OF THE INVENTION (GROUND 1)

“‘[A] sufficient description of a genus... requires the disclosure of either a representative number of species falling within the scope of the genus or structural features common to the members of the genus so that one of skill in the art can ‘visualize or recognize’ the members of the genus.” *Ajinomoto Co., Inc. v. International Trade Commission*, 932 F.3d 1342, 1358-61 (Fed. Cir. 2019) citing (*Ariad*, 598 F.3d at 1350).

Record evidence in this case demonstrates that the patent’s specification describes both a representative number of species *and* common structural features of the narrow set of claimed modified PH20 variants such that POSAs could “‘visualize or recognize’ the members of the genus,” under either the Board’s preliminary construction or Patentee’s proposed construction. Thus, the specification would have conveyed to POSAs that the inventors indeed had possession of the full scope of 95% identical subvariant polypeptides as of December 28, 2012.¹¹ EX2068, ¶¶253-339, 415.

¹¹ As set out in fn. 6, *supra*, sufficiency under §112 is properly judged as of December 28, 2012, the filing date of the ’731 application Merck assessed. Petitioner and its experts erroneously rely upon a December 30, 2011 date (Pet., 31-93; *see also* Pet., 50, 88; EX1003, ¶11), rather than the proper December 28, 2012 date.

A. The Specification Describes Common Structural Features of the Ten I309 Modified PH20 Variants and Their Subvariants

The specification describes and characterizes the common structural features of the ten I309 variants recited in the claims (I309E, I309G, I309H, I309L, I309M, I309N, I309Q, I309R, I309S, and I309T) and their 95% identical subvariants.


As Patentee's experts explain, based on the patent's description and extensive mutagenesis data, POSAs would have understood modified PH20 polypeptides within the scope of the claims to include a common mutation at position 309 to one of ten specified amino acids and 95% identity in primary structure (*i.e.*, amino acid sequence). EX2068, ¶¶269-275; EX2070, ¶¶46-58. They also would have understood the claimed PH20s exhibit the same mechanism of action and share the same characteristic PH20 alpha-beta barrel tertiary structure, including a common active site and the same key catalytic residues, absent changes of the type the patent identifies as inactivating. *Id.*

This is not just conjecture. For example, Dr. Petsko generated homology models of multiply-modified PH20s identified in the patent with the claimed I309 mutation, including chimpanzee PH20, gibbon PH20, orangutan PH20. EX2070,


Petitioner nowhere explains this substantial error—the use of a date a full year earlier—despite the fact that analysis under the proper date was required to establish PGR-eligibility.

¶¶57, 417-434. The modified chimpanzee PH20 contains six modifications when compared to SEQ ID NO: 3. Similarly, the modified orangutan and gibbon PH20s differ at 14 and 17 positions compared to SEQ ID NO: 3, respectively and the modified gibbon PH20 has 21 changes as compared to SEQ ID NO: 44 (which, as Dr. Simpson and Dr. Petsko explain, the '457 publication teaches is active).¹² In other words, they are multiply mutated.

As Dr. Petsko's figures show, these multiply mutated I309N subvariants all share a common tertiary alpha-beta barrel structure:




¹² Dr. Simpson explains that based on the patent alignments and disclosure regarding C-terminal truncations in PH20s, POSAs would have expected that truncating these primate PH20s at the same position as SEQ ID NO: 3 would have produced a soluble, active PH20, and introducing the I309N mutation would similarly have produced an active subvariant. EX2068, ¶¶223-238.



EX2070, ¶¶417-421.

Similarly, these subvariants have common structural features in that residues at 309, 306, 310, 319 are oriented in about the same positions:



EX2070, ¶422.

Thus, POSAs would have understood from the teachings of the patent that the claimed subvariants would share this same tertiary structure unless that structure was broken by inactivating changes of the kind identified by the patent. EX2068, ¶291. Those inactivating changes include changes to the following:

- **Specific amino acid positions in PH20 that are necessary to enzymatic activity** such that they should not be disturbed, such as “positions 25, 111, 113, 176, 189, 203, 246, 249, 252, 316, 341, 346, 352, 400, 402, 408, 423 and 429 of ... SEQ ID NO: 3 or 7 ... since mutagenesis of these residues results in an enzyme that is not active....” EX1001, 68:63-69:4; EX2068, ¶291. The patent further characterizes the roles of these specific amino acid positions in detail, **including**:
 - **Disulfide bridges** - 12 cysteine residues “corresponding to amino acid residue 25, 189, 203, 316, 341, 346, 352, 400, 402, 408, 423 and 429 of ... SEQ ID NO: 3 or 7” that “form disulfide bridges. EX1001, 68:31-43; EX2068, ¶291.
 - **Sites contributing to substrate binding / activity** - The patent also identifies amino acids at positions 111, 113, 249, 176, 246, and 252 of SEQ ID NO: 3 or 7 as “contribut[ing] to substrate binding and/or hyaluronidase activity.” EX1001, 68:51-58; EX2068, ¶291.

The patent also identifies other positions that do not tolerate modification or only tolerate limited modifications. EX2070, ¶¶268, 292-296, 325-342. As Dr. Petsko explains, the POSA would have understood that such positions should be maintained, with some exceptions (like “rescue” mutations that restore activity) that the POSA could determine from the patent data. *Id.*

In other words, because the specification discloses the structural features necessary for activity, POSAs would have understood them as common to active I309 variants and subvariants (further would have been able to reasonably and

reliably distinguish inactive PH20s by changes of the kind identified in the patent as destroying them).

Petitioner thus cannot seriously dispute that the ten I309 variants and their active subvariants share common structural features. Nor is it surprising that these nearly identical sub-variants share common structural features. As Dr. Petsko explains, proteins with far less than 95% sequence identity—in fact proteins with 40% sequence identity—share common structural features down to the atomic level. EX2070, ¶¶95-104, 126-213. Dr. Petsko shows in detail how Hyal-1 and PH20 share common residues critical for activity and stability that are positioned in about the same place and form similar chemical interactions. EX2070, ¶¶126-213. If two hyaluronidases that share less than half of their amino acids have such similarities, then surely the recited I309 variants and their 95% identical active subvariants will share common structural features.

B. The Specification Provides Structure-Function Correlations Allowing for Single and Multiple Mutations


In addition to these common structural features, the specification's working examples provide POSAs with an extensive catalog of modifications at every position of a mature, soluble PH20 (SEQ ID NO: 3), showing which positions tolerate modifications (retain activity) or do not tolerate them (lose activity). EX1001, Example 4, Tables 9-10; EX2068, ¶¶244, 301, 320; EX2070, ¶¶233, 262. These examples provide structure/function correlations POSAs can use to identify

the active 95% identical I309 subvariants and distinguish them from inactive subvariants.

Specifically, as Drs. Petsko and Simpson explain, POSAs would have understood that the '791 patent teaches how to correlate the structure of modified active PH20s—their primary structure and characteristic tertiary structure (an alpha-beta barrel fold)—to the hyaluronidase function of modified PH20. EX2070, ¶¶44, 54, 263-388; EX2068, ¶¶299-301. Through the comprehensive mutagenesis data (Tables 9-10), the patent shows, for each of the 447 positions in SEQ ID NO: 3, the tolerance of each position to substitution as it relates to enzymatic activity. This allows POSAs to distinguish between positions that are (1) critical to activity, (2) generally intolerant in that they permit only very limited substitution, (3) generally tolerant in that they permit a broad range of substitutions. *Id.* The data also identify tolerant positions that retain activity when different types of residues are substituted (*e.g.*, negatively charged, positively charged, large, small, hydrophobic, hydrophilic). *Id.*

To illustrate the structure/function correlation provided by the patent, Dr. Petsko mapped the patent's functional data onto Dr. Park's PH20 homology model, which the parties do not dispute was part of a POSA's knowledge. EX2070, ¶¶95-111, 297-342, 351-352. That mapping is reproduced below in figures showing 90-degree rotations of PH20's tertiary structure, color coded as follows: tolerant

(green), intolerant or generally intolerant (red or orange), and those falling between (aqua). It shows an example of how a POSA would have understood the patent's mutagenesis data in the context of PH20's structure, identifying areas for potential modification and areas to avoid unless the POSA wishes to reduce or eliminate activity:



EX2070, ¶¶297-299.

The '791 patent thus provides the information a POSA requires to identify both single and multiple mutations within various areas of the PH20 structure that can be reasonably predicted to retain hyaluronidase activity, or eliminate it. EX2070, ¶¶54-56, 262-388. This functional map of PH20 identifies for POSAs the extent to which each position in the sequence tolerates substitutions and which do not, which

types of residues at each position are likely to be successful in terms of maintaining activity, and which positions in particular could be targeted to maintain or improve activity.

This detailed structure-function correlation of a narrowly defined, structurally homogeneous genus, demonstrates the inventors were in possession of the full scope of the invention. These data collectively would have provided more than sufficient blaze marks for POSAs to visualize or recognize all the members of the claimed genus, reliably distinguishing actives from inactives. EX2068, ¶¶300, 311; *In re Ruschig*, 379 F.2d 990, 994-995 (CCPA 1967); *Ajinomoto*, 932 F.3d at 1358-61 (adequate description where “skilled artisan could make relatively predictable changes to the native promoter to arrive at a more potent promoter”).

Notably, this is not a case like *Ariad*, as the Board suggested on the limited record pre-institution, where the patent “recite[s] a description of the problem to be solved while claiming all solutions to it and . . . cover[s] any compound later actually invented and determined to fall within the claim’s functional boundaries—leaving it to the pharmaceutical industry to complete an unfinished invention.” *Ariad*, 598 F.3d at 1353; ID at 24.

Indeed, unlike *Ariad* (and *Abbvie*) the patent claims here are exceedingly narrow, and in no way “claim[] all solutions” or even a tiny fraction of the possible solutions to degrading HA with modified PH20s. EX2068, ¶¶260-268. The patent

claims only what was invented; that is what written description asks.

Moreover, for the same reasons, the claims in no way “cover any compound later actually invented and determined to fall within the claim’s functional boundaries.” *Ariad*, 598 F.3d at 1353; ID at 24. Indeed, the claims do not have functional boundaries that would permit this—they have structural ones—even if they do require function. A “later actually invented” protein does not fall into the claims merely by showing hyaluronidase activity; it would have to fall within the narrow structural scope of the claims—the I309 mutation and 95% identity—to be covered. And, as the inventors identified by sequence and structure-function mapping the full scope of the narrow set of claimed I309 variants and subvariants, they in fact possessed the full scope of the genus.


In other words, Patentee received a narrow monopoly in return for contributing its novel 309 mutation *and* a complete characterization of PH20. That is more than sufficient written description.

C. The Example I309 Variants Are Representative of the Claimed 95% Identical Subvariants

POSAs would have understood that the ten I309 variants recited in the claims are representative of their 95% identical subvariants. After all, the subvariants share *at least 95% of their primary structure* with the recited I309 variants. As a result, as Dr. Simpson and Dr. Petsko explain, there is almost no structural diversity within the claimed set of subvariants.

For example, as Dr. Simpson explains, the set of active PH20s with the recited substitution at position 309 share a common structural “scaffold” with minor variations across the surface of the protein’s tertiary structure. EX2068, ¶¶313, 315. As a result, the claimed modified PH20s that are active are structurally homogeneous, and the ten examples of I309 modified PH20s are representative of this narrow set of proteins. *Id.*, ¶314.

Dr. Petsko illustrates this concept in his declaration using examples of multiply mutated PH20 polypeptides that POSAs would have expected to be active based on the disclosure of the patent. EX2070, ¶¶417-432. As is evident from the figure below, the multiply modified PH20 shares the same tertiary structure (the characteristic PH20 alpha-beta barrel fold), with minor modifications dispersed across the surface of the protein, as shown with labeled annotations (A48, G52, A267, R248):



EX2070, ¶¶430-433.

But despite that minor variability, POSAs would understand that these multiply modified subvariant PH20s all share significant structures in common with the I309N variant, as explained above. Dr. Petsko's and Dr. Simpson's analyses show that the claimed I309 variants are representative of the 95% identical subvariants.

Moreover, while the exemplified variants with mutations at the other 446 positions in the protein (other than 309) are not representative species (because they do not meet the claims), they provide valuable information to POSAs in terms of where additional variation in the structure will be tolerated and where it will not. POSAs would understand this information is applicable when making multiply mutated I309 variants. EX2068, ¶¶36, 239-359; EX2070, ¶433. *See Ajinomoto*, 932 F.3d at 1358-61.

Petitioner criticizes these working examples as a "narrow set" because they do not include examples of multiply modified polypeptides. Pet., 67. But Petitioner misunderstands the purpose of the patent's core experiment. By changing every single amino acid in the 447 amino acid sequence of PH20 (SEQ ID NO: 3) to, on average, 13 other amino acids, the inventors were able to map the tolerance of each position to change and to identify those positions that generally tolerate change (and what types of changes) and those that generally do not. As Dr. Petsko explains, POSAs can use those data to determine which positions to modify for both singly

and multiply modified PH20s. EX2070, ¶¶54-56, 262-388.

In the Preliminary Decision, the Board reasoned, based on the limited record in front of it, that the modified PH20 polypeptides were not homogeneous based on the data in the '791 patent disclosing that under 10% of the mutations exhibited increased activity, and that the '791 patent data showed that approximately “57.1% were inactive, and 29.4% had activity <100%.” ID, 33.

But as explained above, Dr. Petsko's and Dr. Simpsons' analyses show that in fact the claimed subvariants are structurally homogeneous. And the large number of inactivating mutations are not evidence of unpredictability. EX2068, ¶¶375-387. To the contrary, the patent data make modifying PH20 predictable by teaching POSAs where to make changes, and perhaps more importantly, where not to make changes, providing predictability.

The Board reasoned that working with PH20 may be unpredictable given of the large number of mutations that inactivate the protein. ID, 21. But the patent solves this problem; the inventors performed the work to identify those positions amenable to substitution. POSAs with the patent in hand can identify active singly and multiply modified subvariants. EX2070, ¶¶343-365; EX2068, ¶¶313-320; *see Ajinomoto*, 932 F.3d at 1358-61 (holding “amount of disclosure necessary to satisfy the written-description requirement 'will necessarily vary depending on the context’” including “predictability of the aspect at issue”; finding four examples sufficient

where POSAs could make “relatively predictable changes”) (citing *Ariad*, 598 F.3d at 1351).

Although inactive variants do not fall within the claimed genus, they are distinguishable from active variants in the same manner and under the same framework. They must include the recited change at position 309 and a primary structure that is at least 95% identical to one of the ten I309 variants. A POSA could identify them, however, as including the types of changes the patent teaches will inactivate the protein—*e.g.*, modifications the POSA would predict abolish activity by disrupting the common structures, such as changes at essential positions in the active site. EX2068, ¶¶376-377. POSAs could thus reliably distinguish actives from inactives.

D. The Patent Teaches the Effect of C-terminal Truncations

Petitioner’s arguments for lack of representativeness and unpredictability consistently ignore the teachings of the patent. For instance, relying on the prior art ’429 patent, Petitioner argues that there is no data in the patent relating to “‘active mutant’ PH20 polypeptides *truncated before position 447*,.” Pet., 47. Petitioner argues this creates uncertainty because, allegedly, the “common disclosure and the prior art report that wild-type PH20 polypeptides terminating at or below position 442 have significantly reduced or no hyaluronidase activity,” citing the ’429 patent which was filed in 2004. *Id.*, 48. Similarly, Petitioner argues that modifications to

SEQ ID NO: 3, which terminates at position 447, cannot be representative of the SEQ ID NOs: 32-66, which terminate between positions 430 and 465, because it alleges the patent does not teach the effect of C-terminal truncations throughout this range.

This is flatly incorrect. Throughout the '791 patent, the inventors discuss U.S. Publication No. US20100143457 (the "'457 publication") in relation to C-terminal truncations in PH20. The '457 publication was filed five years after the '429 patent, and discloses follow-on work to the '429 patent that Halozyme inventors conducted (including one of the '791 patent inventors). This work refined the findings of the '429 patent, providing data showing the effect that serial single amino acid C-terminal truncations had on activity—truncations that run *from position 465 in the mature sequence all the way down to 430*. Additionally, As Drs. Simpson and Petsko further explain, POSAs would have reasonably known based on '457 publication's results what the activity would be for the recited sequence. EX2068, ¶¶321-332; EX2070, ¶¶218-230. Similarly, if a POSA used sequences where the truncation rendered them inactive, they would have remained inactive even after further modification, because they lack the minimum sequence length required for hyaluronidase activity.

Petitioner and its experts did not consider or discuss the '457 publication at all, and thus confess great confusion as to the effect of C-terminal truncations.

POSAs would not have been so confused. The '791 patent in fact guides POSAs to the systematic study of the effect of C-terminal truncations in the '457 publication, and POSAs would have thus understood the effect of combining mutations like those disclosed with respect to SEQ ID NO: 3 with the various C-terminal truncations taught in the '457 publication. EX2068, ¶¶321-332; EX2070, ¶¶384-388, 434.¹³

E. The Specification Describes Multiply Modified PH20 Polypeptides

Finally, Petitioner alleges that the claims capture “multiply modified PH20 polypeptides having changes the disclosure says to omit from ‘active mutants.’” Pet., 73. Petitioner’s argument ignores the specification’s teachings regarding which positions in PH20 tolerate modifications and which positions do not. As discussed above in Section V.A, a POSA would have understood from the specification which subvariants would be expected to be active, unless that activity was broken by inactivating changes of the kind identified by the patent. EX2068, ¶¶290-291. Such

¹³ To the extent Petitioner suggests Patentee need redescribe the results, that is incorrect. *See Immunex Corp. v. Sandoz Inc.*, 964 F.3d 1049, 1063 (Fed. Cir. 2020) (“It is well-established that a patent specification need not re-describe known prior art concepts.”) (citing *Capon v. Eshhar*, 418 F.3d 1349, 1357 (Fed. Cir. 2005) (“The ‘written description’ requirement must be applied in the context of the particular invention and the state of the knowledge.”))

inactivating changes include changes to specific amino acid positions necessary for enzymatic activity, changes to amino acids involved in disulfide bridges, and changes to amino acids at sites contributing to substrate binding/activity. EX1001, 68:31-43, 68:51-58, 68:63-69:4; EX2068, ¶¶290-291. The patent also identifies other positions that do not tolerate modification or only tolerate limited modifications. EX2070, ¶¶292-296. As Dr. Petsko explains, the POSA would have understood that such positions should be maintained, with some exceptions (like “rescue” mutations that restore activity) that the POSA could determine from the patent data. *Id.* Additionally, as discussed below in Section VI.C, any inactive mutant embodiments simply do not meet the claims. “Even if some of the claimed combinations [are] inoperative, the claims are not necessarily invalid.” *Atlas Powder*, 750 F.2d at 1576.

Moreover, the claims do cover multiply modified polypeptides with the following changes: N47A/N131A, N47A/N219A, N131A/N219A and N47A/N131A/N219A in addition to the recited substitution at position 309 (for example, I309N). And, as Dr. Petsko and Dr. Simpson explain, POSAs would have expected the resulting multiply modified PH20 polypeptide to be active because the ’457 publication teaches that the multiply modified proteins (without the modification at position 309) were active. EX2068, ¶¶335-336; EX2070, ¶¶214-15. POSAs would have expected that introducing the modification at position 309 as

taught in the '791 patent into one of these multiply modified PH20s would have produced an active subvariant. EX2068, ¶337; EX2070, ¶¶214-230, 417-432.

F. *AbbVie* Is Distinguishable

In the Institution Decision, the Board reasoned on the limited record in front of it that “[t]hese facts are analogous to those in *AbbVie Deutschland GmbH & Co., KG v. Janssen Biotech, Inc.*, 759 F.3d 1285, 1300 (Fed. Cir. 2014), where the claims contained structurally diverse antibodies, but the patent at issue only described structurally similar antibodies.” ID, 24. As set out above and shown definitively by Dr. Petsko, however, the genus of the claims here contains structurally homogeneous modified PH20s. The claims are thus not directed to a structurally diverse genus, as in *AbbVie*, but to ten variants and their 95% identical sub-variants. Moreover, the working examples comprehensively characterize the structure-function of PH20 (SEQ ID NO: 3) through the mutagenesis data. In *AbbVie*, there were no working examples to illuminate the common structures of the diverse genus claimed. Thus, *AbbVie* is not on point.

G. The Petition Fails To Demonstrate That The Challenged Dependent Claims Lack Written Description

Petitioner contests the written description of the dependent claims only on the same grounds addressed above, and thus its challenge fails for the same reasons. Pet., 74-76; EX2068, ¶339, Section IX.

VI. THE CHALLENGED CLAIMS ARE ENABLED (GROUND 2)

Enablement requires that the specification teach POSAs how to make and use the full scope of the claimed invention without undue experimentation. *In re Wands*, 858 F.2d 731, 737 (Fed. Cir. 1988). Record evidence demonstrates that the patent’s specification provides precisely that: a detailed structure-function correlation that enables POSAs to predictably practice the full scope of the claims.

There is no dispute that POSAs could readily generate claimed PH20 variants with amino acid substitutions and test them for activity using routine molecular biology and biochemistry techniques. Pet., 47-49. The “key enablement question,” as explained in *Idenix* as cited by the Board, is whether “a person of ordinary skill in the art would know, without undue experimentation, which species would be effective.” ID, 35 (citing *Idenix*).

They would. As an initial matter, the challenged claims do not encompass an “immense genus” of unrelated polypeptides, as Petitioner contends (Pet., 79), but instead ten variants with the I309 mutation and a narrowly defined and structurally homogeneous set of PH20 subvariants with 95% sequence identity. *See* Sections V.A, C. Each claimed polypeptide must (i) include a defined substitution at position 309, and (ii) share at least 95% sequence identity with SEQ ID NO: 35. EX2068, ¶¶251. POSAs would recognize, within this narrow genus, that the ten variants and their subvariants are structurally homogeneous in that they share at least 95%

identical primary structure, the I309 mutation, and for those that are active, the same PH20 tertiary structure and several common structural features, such as the same common residues critical for catalysis; moreover, POSAs can distinguish actives from inactives by the absence of the common structural features in the inactives (e.g. changes to “scaffolding” such as disulfide bridges or modification of catalytic residues). EX2068, ¶¶269-275, 300, 313; EX2070, ¶¶49-51, 53, 248-253, 325-342, 390-432. This dual limitation to a single mutation and only a small range of subvariants leaves POSAs with a narrow, well-defined set of PH20 variants with common structural characteristics, not the vast, unpredictable, “immense genus” Petitioner describes.

Within this narrow and homogeneous set of PH20 variants, the patent provides extensive mutagenesis data across a full, mature, soluble PH20 sequence (SEQ ID NO: 3) that give POSAs predictive insight into which substitutions preserve activity and which abolish it. By systematically testing (on average 13 and up to 18) substitutions at every amino acid position in SEQ ID NO: 3, the patent shows the substitutions that consistently destroy activity by eliminating, for instance, catalytic residues or disulfide-forming cysteines. Similarly, buried residues important for protein structure or involved in orienting secondary structures to achieve the characteristic alpha-beta barrel fold are generally intolerant to change. EX2068, ¶310; EX2070, ¶¶325-333. By contrast, changes in certain peripheral loops or

solvent-exposed regions are more likely to be tolerated with little effect on function. EX2070, ¶¶317-24. Some positions tolerate some types of substitutions but not others. EX2070, ¶¶279-282.

Taken as a whole, these data provide significant guidance to POSAs in terms of what changes to make at which positions. This guidance gives POSAs a how-to for designing and using the claimed PH20 variants and subvariants without undue experimentation. This is sufficient for enablement, as the Supreme Court explained in *Amgen*:

That is not to say a specification always must describe with particularity how to make and use every single embodiment within a claimed class. For instance, it may suffice to give an example (or a few examples) if the specification also discloses ‘some general quality ... running through’ the class that gives it “a peculiar fitness for the particular purpose. In some cases, disclosing that general quality may reliably enable a person skilled in the art to make and use all of what is claimed, not merely a subset.

Amgen, 598 U.S. at 610-611. Here, based on the patent’s working examples and extensive mutagenesis data identifying common structures, POSAs can reasonably distinguish between active and inactive modified PH20 variants, and can predictably make and use either type of variant, whether singly or multiply mutated.

Patentee addresses the *Wands* factors individually below.

A. The *Wands* Factors Weigh in Favor of Enablement

1. Scope of Claims and Nature of the Invention

As discussed in Section V.A-C, the challenged claims recite a narrow and structurally homogeneous genus of ten PH20 variants with one of ten substitutions at position I309, as well as subvariants of each that must maintain at least 95% sequence identity. The scope of the claims is extremely narrow. While Petitioner focuses on the raw number of the subvariants, this is not how a POSA would consider the scope of the genus (EX2068, ¶¶349-356) because it misses the forest for the trees. The claims require the “modified PH20 polypeptides” to have a previously undiscovered mutation at a single position in the sequence. They would consider the scope of the claims by considering the variation across the claimed set of proteins. *Id.* As set out above, there is only minor variation—5% variation within primary sequence—such that the enzymatically active claimed variants and subvariants share common structures, including the same alpha-beta barrel tertiary structure and common “scaffolding” (*e.g.* disulfide bonds). *Id.*

As to the nature of the invention, As Dr. Simpson explains, POSAs would have understood that making active or inactive modified PH20 polypeptides required only routine molecular biology and protein biochemistry techniques in view of the patent’s teachings. EX2068, ¶¶340-359; EX1001, 141:22-143:16.

Petitioner, for its part, did not make a serious attempt to understand the nature of the invention. Petitioner primarily relies on its expert's opinion that proteins, in general, are unpredictable when mutated. But Petitioner's experts have zero experience with the actual subject matter of the invention—PH20s, or even hyaluronidases in general. EX2077, 13:10-17; EX2076, 64:9-13, 67:1-8. And they dismissed the mutagenesis data disclosed in the patent as “no guidance.” EX1003, ¶195.

The nature of the invention, however, is not proteins in general. The invention is modified PH20 variants with a defined set of structures, which the inventors characterized via expansive disclosure in the specification regarding the tolerance of every position in a mature, soluble, active PH20 sequence to modification, making modification (and the nature of the invention) reasonably predictable. Thus, as Patentee's experts show, given the nature of the particular invention claimed—a structurally homogeneous set of PH20s—with the knowledge in the art and the mutagenesis data, POSAs could reasonably identify and predictably make and use the subvariants. *Id.*

Accordingly, the nature of the invention and the scope of the claims weigh strongly in favor of enablement under the *Wands* factors.

2. Level of Skill in the Art And State of the Art

As set forth in Section III, Patentee applies Petitioner's definition of a POSA,

who would have had an undergraduate degree, a Ph.D., and post-doctoral experience in scientific fields relevant to study of protein structure and function and would have been familiar with factors influencing protein structure, folding and activity, production of modified proteins using recombinant DNA techniques, and use of biological assays to characterize protein function, as well as with techniques used to analyze protein structure (i.e., sequence searching and alignments, protein modeling software, etc.). ID, 8-9.

Patentee also notes that it is undisputed that POSAs would have been able to speak with someone with hyaluronidase experience as part of a multi-disciplinary team. EX2076, 63:8-64:2.

As set forth in Section II.B, the structural biology of hyaluronidases was well developed as of December 28, 2012. For instance, by then, the crystal structures of bee venom hyaluronidase and human Hyal-1 had been solved (EX1033; EX1006), and it was undisputed that these structures allowed POSAs to generate accurate homology models of PH20's tertiary structure. Petitioner's own expert confirmed that by 2011 it was routine for POSAs to model PH20 and assess amino acid substitutions in that structural context. EX2077, 94:4-22, 176:2-5.

The art also recognized that hyaluronidases, despite only 30-40% sequence identity, share a conserved alpha-beta barrel fold, a common active site, and a conserved set of catalytic residues positioned similarly across Hyal-1, bee venom

hyaluronidase, and PH20. EX1006, 6912, 6914; EX1008, 826, 833; EX1033, 1028; EX2070 ¶¶126-27. Mutagenesis studies in Hyal-1 and PH20 had further confirmed the criticality of these residues for enzymatic activity and stability. EX1010; EX1011; EX1033, 1029; EX2070 ¶¶167-206; EX2068 ¶¶106-153, 365.

Accordingly, as of December 28, 2012, POSAs, already possessed a high degree of skill and the tools and knowledge to model PH20 accurately, assess potential substitutions, and interpret their effects based on well-characterized structural and mechanistic features shared across hyaluronidases. Given this developed state of the art, the specification's disclosures provided more than sufficient guidance to enable the full scope of the claimed modified PH20 polypeptides without undue experimentation. EX2068 ¶¶359, 368; EX2070, ¶¶52, 234, 262.

3. Guidance in the Specification and the Presence of Working Examples

As set forth in Sections II.C and V.B, the specification supplies detailed instructions on how to make and used the claimed variants and sub-variants. EX1001, 67:30-69:65, 71:19-27, Tables 5, 9–10; EX2068, ¶¶369-374; EX2070, ¶¶248-61.

Together, these disclosures provide a structure-function correlation for PH20 that informs POSAs which regions are essential, which resist change, and which can accommodate or even benefit from substitution. With this map, along with the

routine use of homology modeling, POSAs could readily distinguish between actives and inactives, whether singly or multiply mutated, to practice the invention. EX2070, ¶¶54-56, 262-388; EX2068, ¶¶154-160, 244-245, 312, 320, 370-372, 376-381. As Dr. Simpson testifies, “[a]s someone with decades of experience studying hyaluronidases, including common structural features and structure-function correlations for hyaluronidases, I cannot emphasize enough the value of these data to a POSA in the field.” *Id.*, ¶373.

Moreover, the inventors provided working examples of the ten variants of the I309 mutation recited in the claims. Given the extensive experimental data fleshing out the functional map of PH20, further working examples of the subvariants are not necessary. *See* Section V.B-C; EX1001, 199:10-267:26, Tables 8–10, 288:49-290:55; EX2068, ¶374.

The specification also provides guidance on how to use the claimed modified PH20 polypeptides. It teaches, for instance, that modified PH20s are useful as spreading factors to increase delivery and bioavailability of subcutaneously administered therapeutic agents—a fact not in dispute. 179:55-61.

The specification’s guidance, reinforced by its extensive working examples, therefore weighs strongly in favor of enablement.

4. Predictability of the Field and Quantity of Experimentation

As set forth in Section V.A-C, the specification’s identification of common

structural features and the associated correlation it provides between PH20s structure and hyaluronidase activity makes the effects of modifications to PH20 reasonably predictable. *See also*, EX2070, ¶¶263-342, 389-434; EX2068, ¶¶375-387.

Moreover, POSAs could and would have used routine homology modeling to reinforce this predictability, making any experimentation routine. EX1004, ¶¶36-38; EX2076, 93:4-22; EX2077, 53:22-54:5; EX2070, ¶¶117-120, 297-352. Both Hecht and Park admitted that homology modeling was widely available and would be used to assess whether substitutions were likely to be tolerated.

And Dr. Petsko describes in detail how POSAs could use the functional data in connection with homology models known in the art to make active subvariants. For example, Dr. Petsko mapped the functional data on the homology model and provided multiple examples of how POSAs would have used the data in connection with the homology model to make modified PH20s using routine methods and illustrating how a POSA would have predictably and easily used with the data without trial-and-error experimentation. EX2070, ¶¶297-342. As Dr. Simpson explains, “[t]he immense disclosure in the specification makes generating and using the modified PH20 variants and sub-variants in the claims predictable. That is because the detailed structure-function map provided by the patent allows POSAs to reasonably predict, using their structural biology knowledge, whether substitutions are likely to retain or abolish enzymatic activity.” EX2068, ¶381.

In view of this guidance, the quantity of experimentation required would not have been undue. Petitioner's assertion that POSAs would need to screen an "immense number" of variants is misplaced because the specification itself already discloses extensive data showing which substitutions preserve activity and which eliminate it. EX1001, Tables 9–10; EX2068, ¶¶375-381, 385-387; EX2070, ¶¶52, 234, 262. No doubt Petitioner argues that POSAs would have to screen because the term "screening" suggests POSAs must engage in trial-and-error experimentation to practice the claims. But that simply is wrong. The patent teaches POSAs how to make the claimed variants with no "screening" required.

And Petitioner's argument that POSAs would need to generate impossibly large libraries and screen them for activity to practice the claims is not credible. Where, as here, the patent teaches POSAs a structure-function map of PH20, including which changes to make and which positions are generally tolerant to change, there is no reason to randomly screen to identify active PH20s with the I309 mutation. POSAs seeking to make PH20s through random screening would be, in effect, ignoring the teachings of the specification.

Finally, relying on Dr. Hecht, Petitioner argues that there was supposedly uncertainty "about the activity of truncation mutants in the C-terminal region of PH20." EX1003, ¶100. Patentee addressed this point above in Sections II.C.5 and V.D. Petitioner's expert appears to not even have considered the relevant teaching

in the '457 publication, which is discussed throughout the '791 patent. EX1003, ¶19; EX1004, ¶9. Dr. Simpson explains what a POSA would have reasonably and reliably expected when making mutations in PH20s of varying lengths, including those that terminate before or after position 447. EX2068, ¶¶184, 326-327, 382.

In sum, POSAs would have relied on the patent's disclosure, which could be supplemented by routine modeling, to make and use the claimed modified PH20 variants and sub-variants using only routine methods well within the skill of the art. EX2068, ¶¶340-390. Accordingly, the specification provides the framework for POSAs to predictably make and use the full scope of both active and inactive PH20 polypeptides, weighing strongly in favor of enablement.

B. Specification Enables Credible Use of the Claimed PH20 Variants

Having shown that POSAs could make and distinguish the claimed variants, the record also establishes that the specification teaches how to use them.

The specification expressly teaches that the claimed PH20 variants with enzymatic activity can be used as spreading factors to enhance the delivery and bioavailability of subcutaneously administered therapeutic agents. EX1001, 179:55-61. This was a well-recognized application in the field, and Petitioner does not dispute that active modified PH20 variants within the claims provide that established utility—only that they can be identified, which is addressed above. Petitioner does not challenge this use.

Petitioner instead challenges the utility of inactive variants as contraceptives, contending (at 28 and 63) it is “implausible” and has no “scientific credibility.” But Patentee does not dispute that the claims require modified PH20s with at least some activity, so the utility of inactive modified PH20s is irrelevant.

C. A POSA Could Readily Distinguish Between Active And Inactive Mutants

Petitioner argues that the specification “implausibly contends” that inactive mutants are useful as a contraceptive antigen, and that other mutants that do not fold or express will “have no utility at all.” Pet., 79. If true (it is not), that argument is irrelevant because inactive modified PH20s do not satisfy the claims. The relevant question is whether undue experimentation would have been required to distinguish the operative variants. *Atlas Powder Co. v. E.I. Dupont De Nemours*, 750 F.2d 1569, 1576 (Fed. Cir. 1984); *see also Pharmaceutical Resources, Inc. v. Roxane Laboratories, Inc.*, 253 F. App’x 26, 29–30 (Fed. Cir. 2007).

As noted above, the specification, together with well-established tools in the art, provided the means to identify the operative variants and sub-variants. As discussed in Section V-VI, the functional map disclosed in the patent, reinforced by extensive working examples, identifies PH20’s critical residues, tolerant regions, and the consequences of specific substitutions. EX1001, 176:29-179:50, 229:58-232:37; EX2068, ¶¶239-332; EX2070, ¶¶248-296. With this disclosure, POSAs could apply routine sequence alignment and homology modeling software, both

widely available by December 28, 2012, to predict whether a variant would be active or inactive, and then readily confirm that prediction using standard testing methods. EX2096, 268; EX2097, ¶¶[0666]-[0679]; EX2098, 39–40; EX2099, 262; EX2068, ¶¶312, 345, 347, 357; EX2070, ¶¶87-111, 343-352; As the Federal Circuit has held, “[e]nablement is not precluded by the necessity for some experimentation.” *In re Wands*, 858 F.2d 731, 737 (Fed. Cir. 1988). Because the map delineates intolerant regions, POSAs would have immediately recognized these inoperative embodiments as falling outside tolerated substitutions and thus the scope of the claims.

Accordingly, POSAs reading the specification in light of the general knowledge in the art would have been able to identify inactive versus active polypeptides without undue experimentation.

D. The Challenged Dependent Claims Are Enabled

Petitioner contests the enablement of the dependent claims only on the same grounds addressed above, and thus its challenge fails for the same reasons. 1. Pet., 92-93; EX2068, ¶¶388-390; EX2070, ¶¶343-88.

VII. CONCLUSION

Petitioner fails to meet its burden of persuasion in this proceeding. The Board should reject the Petition and find all of the challenged claims not unpatentable.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX PLLC

/R. Wilson Powers III/

R. Wilson Powers III, Ph.D.
Registration No. 63,504
Attorney for Patent Owner

Date: January 16, 2026

1101 K Street, NW, 10th Floor
Washington, DC 20005
(202) 371-2600

CERTIFICATE OF WORD COUNT (37 C.F.R. § 42.24(d))

1. This Patent Owner Response complies with the type-volume limitation of 18,700 words, comprising 12,895 words, excluding the parts exempted by 37 C.F.R. § 42.24(a)(1).

2. This Patent Owner Response complies with the general format requirements of 37 C.F.R. § 42.6(a) and has been prepared using Microsoft® Word in 14-point Times New Roman font.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX PLLC

/R. Wilson Powers III/

R. Wilson Powers III, Ph.D.
Registration No. 63,504
Attorney for Patent Owner

Date: January 16, 2026

1101 K Street, NW, 10th Floor
Washington, DC 20005
(202) 371-2600

CERTIFICATE OF SERVICE (37 C.F.R. § 42.6(e))

I certify that the above-captioned **PATENT OWNER RESPONSE**
UNDER 37 C.F.R. § 42.120 and Exhibits 2068-2071, 2076-2080, 2082-2094,
2096-2099, 2163-2166, 2168-2170, 2174-2191, and 2193-2200 were served in
their entireties on January 16, 2026, upon the following parties via electronic mail:

Jeffrey P. Kushan (Lead Counsel)	jkushan@sidley.com
Leif Peterson (Back-up Counsel)	leif.peterson@sidley.com
Sue Wang (Back-up Counsel)	sue.wang@sidley.com
Katherine A. Helm (Back-up Counsel)	khelm@dechert.com
Blaine Hackman (Back-up Counsel)	Blaine.Hackman@dechert.com
Amy Mahan (Back-up Counsel)	amy.mahan@sidley.com
Christine M. Engen (Back-up Counsel)	christine.engen@sidley.com
Amit Bhatla (Back-up Counsel)	abhatla@sidley.com
Brian M. Goldberg (Back-up Counsel)	Brian.Goldberg@dechert.com
Mark Stewart (Back-up Counsel)	mark.stewart@merck.com
	HalozymePGRs@sidley.com

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX PLLC

/R. Wilson Powers III/

R. Wilson Powers III, Ph.D.
Registration No. 63,504
Attorney for Patent Owner

Date: January 16, 2026

1101 K Street, NW, 10th Floor
Washington, DC 20005
(202) 371-2600